GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Bladder | ON | Recruiting
SL01-DEL-101
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Dr. Lini Pandie & Dr. Fatima Rangwala
Start Date: March 26, 2019

NCT #: NCT03894618

SPONSOR: Shattuck Labs, Inc. 

INFO: https://clinicaltrials.gov/ct2/show/NCT03894618?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=9

CONTACT: 984-329-5231

OTHER CANADIAN CENTRES:

1. Princess Margaret Cancer Center (Toronto): Lillian.Siu@uhn.ca

 

Bladder | ON | Active, not recruiting
NCI-2019-01035, ETCTN 10183
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Dr. Di Maria Jiang (UHN Lead)
Start Date: March 17, 2019

NCT #: NCT03854474

SPONSOR: National Cancer Institute (NCI)

INFO: https://clinicaltrials.gov/ct2/show/NCT03854474?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=3

CONTACT:  416-946-4501

 

Renal | ON | Recruiting
3D Ultrasound
(3D) Ultrasound Imaging Liver and Kidney
Dr. Aaron Fenster
Start Date: February 18, 2019

NCT #: NCT03844399

SPONSOR: Western University (London)

INFO: https://clinicaltrials.gov/ct2/show/NCT03844399?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=4

CONTACT:  519-931-5777

Bladder | AB, BC, ON, QC, SK | Recruiting
BL13
A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer
Dr. Wassim Kassouf (MUHC)
Start Date: December 21, 2018

NCT #: NCT03768570

SPONSOR: CCTG in collaboration with AstraZeneca

INFO: https://clinicaltrials.gov/ct2/show/NCT03768570

CONTACT: (514) 934-8246

OTHER CANADIAN CENTRES:

1. Tom Baker Cancer Centre (Calgary): 403-521-3445                                                         
2. Cross Cancer Institute (Edmonton): 780-432-8762                                                                    
3. BCCA Vancouver Cancer Centre: 604-877-6000                                                                        
4. Juravinski Cancer Centre (Hamilton): 905-387-9495                                                                                
5. Kingston Health Sciences Centre: 613-533-6463 x 78769                                                 
6. London Regional Cancer Program: 519-685-8261                                                       
7. Stronach Regional Health Centre (Newmarket): 905-685-4521 x 6596                                           
8. Ottawa Hospital Research Institute: 613-737-7700 x 70180                                             
9. Health Sciences North (Sudbury): 705-522-6237                                                        
10. Thunder Bay Regional Health Sciences Centre: 807-684-7566                                      
11. University Health Network (Toronto): 416-946-4501 x 2520                                 
12. The Jewish General Hospital (Montreal): 514-398-8307                                        
13. The Research Institute of McGill University (Montreal): 514-934-8246                     
14. Allan Blair Cancer Centre (Regina): 306-755-2691                                                         
15. Saskatoon Cancer Centre: 306-655-2710                                                         
 

Prostate | QC | Recruiting
2019-4650
Single Fractions SBRT for Prostate Cancer
Dr. Fabio Cury
Start Date: November 8, 2018

NCT #: NCT04004312

SPONSOR: McGill University Health Centre in collaboration with Boston Scientific Corporation

INFO: https://clinicaltrials.gov/ct2/show/NCT04004312

CONTACT:  514-934-1934 ext 43191

Renal | ON | Recruiting
18-5481
SABR for Renal Tumors
Dr. Joelle Helou
Start Date: November 1, 2018

NCT #:  NCT03747133

SPONSOR: University Health Network

INFO: https://clinicaltrials.gov/ct2/show/NCT03747133?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=19

CONTACT:  416-946-4501 x 4866

OTHER CANADIAN CENTRES: Royal Victoria Regional Health Centre (Barrie)

 

Prostate | ON | Recruiting
PREP
PSMA-PET Registry for Recurrent Prostate Cancer (PREP)
Dr. Glen Bauman
Start Date: September 27, 2018

NCT #: NCT03718260

INFO:  https://clinicaltrials.gov/ct2/show/NCT03718260

CONTACT:  Catherine Hildebrand // 519-685-8500 ext 53535

Prostate | BC | Recruiting
LDR/HDRmono
LDR vs. HDR Brachytherapy for Prostate Cancer
Dr. Helperin Ross
Start Date: February 15, 2018

NCT #: NCT03426748

SPONSOR: British Columbia Cancer Agency in collaboration with BC Cancer Foundation

INFO: https://clinicaltrials.gov/ct2/show/NCT03426748

CONTACT:  250 712 3958

Prostate | AB, BC, NS, ON, QC, SK | Recruiting
1234G
A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
Dr. Zineb Hamilou (CHUM)
Start Date: December 12, 2017

NCT #: NCT03385655

INFO: https://clinicaltrials.gov/ct2/show/NCT03385655

CONTACT:

(514) 890-8000 Ext. 20688

Prostate | AB, BC, NS, ON, QC, SK | Recruiting
1234C
A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234
Dr. Michael Ong (OHRI)
Start Date: December 12, 2017

INFO:: https://clinicaltrials.gov/ct2/show/NCT03385655

CONTACT:  (613) 737-7700 Ext. 75051

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy